To evaluate the efficacy of injecting platelet rich plasma in osteoarthritis knee and its relation with MAT2B gene
Phase 4
- Conditions
- Health Condition 1: M171- Unilateral primary osteoarthritisof knee
- Registration Number
- CTRI/2020/02/023376
- Lead Sponsor
- niversity College Of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)Age >45 years and <65 years
2)Diagnosed case of osteoarthritis knee based on clinico- radiological diagnosis
3)In case of bilateral symptoms side with more significant symptom receives treatment
4)NRS score of >=4/10 over minimum 3 months
5)Grade 1, 2, 3 of Kellgren and Lawrence system of classification of severity of knee
OA(28)
6)Patients who have tried atleast 3 months of non-invasive conservative treatment
including lifestyle modification before the beginning of therapy
Exclusion Criteria
1)Diagnosis of secondary OA (Post-traumatic, post-surgical and post-inflammatory
osteoarthritis)
2)Recent intra-articular injection of corticosteroids within last 3 months and prior treatment
with hyaluronic acid in past 6 months
3)Anemia (Hb < 10gm%)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score, <br/ ><br>stiffness score, physical function score and WOMAC total score at various designated <br/ ><br>intervals <br/ ><br>2)NRS pain score at various designated intervalsTimepoint: baseline and at the end of 1st week, 2nd week, 4th week, 8th week and 12th week
- Secondary Outcome Measures
Name Time Method 1)Lequesne scores following implementation of injection at various designated intervals <br/ ><br>2)Neuropathic component of pain using NPSI scores at various designated intervals <br/ ><br>3)The quality of life QoL usng SF-12 questionnaire scores at various designated <br/ ><br>intervals <br/ ><br>4)Modulation in mRNA expression of MAT2B genes at baseline and after 12 weeks <br/ ><br>following intra-articular treatment.Timepoint: baseline and at the end of 1st week, 2nd week, 4th week,6th week,8th week and 12th week. <br/ ><br>